デフォルト表紙
市場調査レポート
商品コード
1698043

筋弛緩薬市場- 世界の産業規模、シェア、動向、機会、予測、薬物タイプ別、投与経路別、流通チャネル別、地域別、競合別、2020-2030年

Muscle Relaxant Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type, By Route of Administration, By Distribution Channel, By Region & Competition, 2020-2030F


出版日
ページ情報
英文 185 Pages
納期
2~3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.87円

こちらのレポートには、数時間(ご購入金額の10%)分のアナリストへの質問/追加調査サービスが含まれております。

筋弛緩薬市場- 世界の産業規模、シェア、動向、機会、予測、薬物タイプ別、投与経路別、流通チャネル別、地域別、競合別、2020-2030年
出版日: 2025年03月28日
発行: TechSci Research
ページ情報: 英文 185 Pages
納期: 2~3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

筋弛緩薬の世界市場規模は2024年に38億5,000万米ドルとなり、予測期間では2030年までCAGR 4.40%で安定した成長が予測されています。

筋弛緩薬の世界市場は製薬産業の重要なセグメントを構成しており、筋肉の痙攣、硬直、不随意収縮を緩和するために設計された医薬品の研究、開発、生産、流通、商品化を網羅しています。これらの薬剤は神経経路を標的とし、中枢神経系(CNS)に直接作用するか、末梢神経の活動を調節して筋弛緩を促進します。筋緊張、捻挫、慢性腰痛、線維筋痛症、多発性硬化症、神経疾患に伴う痙縮の治療に広く処方されています。

市場概要
予測期間 2026-2030
市場規模:2024年 38億5,000万米ドル
市場規模:2030年 50億米ドル
CAGR:2025年~2030年 4.40%
急成長セグメント 経口
最大市場 北米

主に筋骨格系疾患の罹患率の上昇、世界人口の高齢化、医薬品製剤の進歩が市場の急拡大に拍車をかけています。慢性疼痛や運動関連疾患の増加により、効果的で忍容性の高い筋弛緩薬に対する需要が高まっています。さらに、人口動態の動向、特に高齢者の割合の増加が市場の成長をさらに後押ししています。高齢者は関節炎、骨粗鬆症、腰痛にかかりやすく、これらすべてが筋弛緩薬療法を必要とするからです。

主な市場促進要因

筋骨格系疾患の有病率の上昇

主な市場課題

ジェネリック医薬品との競合

主要市場動向

生物製剤と新規治療

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 筋弛緩薬市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 薬剤の種類別(骨格筋弛緩薬、顔面筋弛緩薬、神経筋遮断薬)
    • 投与経路別(経口、注射、その他)
    • 流通チャネル別(病院薬局、小売薬局、オンライン薬局)
    • 地域別
    • 企業別(2024)
  • 市場マップ

第6章 北米の筋弛緩薬市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 北米:国別分析
    • 米国
    • カナダ
    • メキシコ

第7章 欧州の筋弛緩薬市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 欧州:国別分析
    • ドイツ
    • 英国
    • イタリア
    • フランス
    • スペイン

第8章 アジア太平洋地域の筋弛緩薬市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • アジア太平洋地域:国別分析
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア

第9章 南米の筋弛緩薬市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 南米:国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカの筋弛緩薬市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 中東・アフリカ:国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 最近の動向
  • 製品上市
  • 合併と買収

第13章 世界の筋弛緩薬市場:SWOT分析

第14章 競合情勢

  • Amneal Pharmaceuticals LLC
  • Ipsen Biopharmaceuticals Inc
  • Merz Pharmaceuticals LLC
  • Par Pharmaceutical Inc
  • Endo Pharmaceuticals Inc
  • Vertical Pharmaceuticals Inc
  • Mallinckrodt LLC
  • Sterix Ltd
  • Eisai Co Ltd
  • Teva Pharmaceuticals USA Inc.

第15章 戦略的提言

第16章 調査会社について・免責事項

目次
Product Code: 17190

Global Muscle Relaxant Drugs Market was valued at USD 3.85 Billion in 2024 and is anticipated to project steady growth in the forecast period with a CAGR of 4.40% through 2030. The Global Muscle Relaxant Drugs Market constitutes a vital segment of the pharmaceutical industry, encompassing the research, development, production, distribution, and commercialization of medications designed to relieve muscle spasms, stiffness, and involuntary contractions. These drugs operate by targeting neurological pathways, either directly affecting the central nervous system (CNS) or modulating peripheral nerve activity, thereby promoting muscle relaxation. They are extensively prescribed for treating muscle strains, sprains, chronic back pain, fibromyalgia, multiple sclerosis, and spasticity associated with neurological conditions.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 3.85 Billion
Market Size 2030USD 5.00 Billion
CAGR 2025-20304.40%
Fastest Growing SegmentOral
Largest MarketNorth America

The market is undergoing rapid expansion, primarily fueled by the rising incidence of musculoskeletal disorders, an aging global population, and advancements in pharmaceutical formulations. The increasing prevalence of chronic pain and mobility-related conditions has intensified the demand for effective, well-tolerated muscle relaxants. Additionally, demographic trends particularly the growing proportion of elderly individuals have further propelled market growth, as older adults are more susceptible to arthritis, osteoporosis, and lower back pain, all of which necessitate muscle relaxant therapy.

Key Market Drivers

Rising Prevalence of Musculoskeletal Disorders

The increasing prevalence of musculoskeletal disorders (MSDs) is a major driving force behind the expansion of the Global Muscle Relaxant Drugs Market. MSDs encompass a wide range of conditions affecting the bones, muscles, ligaments, tendons, and joints, leading to chronic pain, reduced mobility, and functional impairments. The incidence of MSDs has risen sharply due to aging populations, sedentary lifestyles, workplace injuries, and increasing rates of obesity. According to the World Health Organization (WHO), an estimated 1.71 billion people worldwide are affected by musculoskeletal disorders, including lower back pain, neck pain, osteoarthritis, and rheumatoid arthritis. These conditions represent a significant global burden, driving the demand for effective treatment solutions within the pharmaceutical and healthcare industries, making them the leading cause of disability. Chronic conditions such as arthritis, lower back pain, and fibromyalgia have significantly increased the need for muscle relaxants to manage pain and improve quality of life.

Key Market Challenges

Competition from Generic Drugs

As patents for certain muscle relaxant drugs expire, the market faces increased competition from generic drug manufacturers. This competition can lead to price erosion and reduced profit margins for original drug developers. Pharmaceutical companies must navigate this challenge by differentiating their products through innovation, improved formulations, and enhanced therapeutic outcomes.

Key Market Trends

Biologics and Novel Therapies

The emergence of biologics and novel therapies is reshaping the treatment landscape. Biologics, which are derived from living organisms, offer the potential for targeted interventions with fewer side effects. As research into biologics and advanced therapies progresses, new avenues for addressing musculoskeletal disorders may emerge, providing patients with innovative treatment options.

Key Market Players

Amneal Pharmaceuticals LLC

Ipsen Biopharmaceuticals Inc

Merz Pharmaceuticals LLC

Par Pharmaceutical Inc

Endo Pharmaceuticals Inc

Vertical Pharmaceuticals Inc

Mallinckrodt LLC

Sterix Ltd

Eisai Co Ltd

Teva Pharmaceuticals USA Inc

Report Scope:

In this report, the Global Muscle Relaxant Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Muscle Relaxant Drugs Market, By Drug Type:

  • Skeletal Muscle Relaxant Drugs
  • Facial Muscle Relaxant Drugs
  • Neuromuscular Blocking Agents

Muscle Relaxant Drugs Market, By Route of Administration:

  • Oral
  • Injectable
  • Others

Muscle Relaxant Drugs Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Muscle Relaxant Drugs Market, By region:

  • North America
    • United States
    • Mexico
    • Canada
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • India
    • South Korea
    • Japan
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Muscle Relaxant Drugs Market.

Available Customizations:

Global Muscle Relaxant Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Muscle Relaxant Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Type (Skeletal Muscle Relaxant Drugs, Facial Muscle Relaxant Drugs, Neuromuscular Blocking Agents)
    • 5.2.2. By Route of Administration (Oral, Injectable, Others)
    • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 5.2.4. By Region
    • 5.2.5. By Company (2024)
  • 5.3. Market Map

6. North America Muscle Relaxant Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Type
    • 6.2.2. By Route of Administration
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Muscle Relaxant Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Type
        • 6.3.1.2.2. By Route of Administration
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada Muscle Relaxant Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Type
        • 6.3.2.2.2. By Route of Administration
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico Muscle Relaxant Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Type
        • 6.3.3.2.2. By Route of Administration
        • 6.3.3.2.3. By Distribution Channel

7. Europe Muscle Relaxant Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Type
    • 7.2.2. By Route of Administration
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Muscle Relaxant Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Type
        • 7.3.1.2.2. By Route of Administration
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. United Kingdom Muscle Relaxant Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Type
        • 7.3.2.2.2. By Route of Administration
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. Italy Muscle Relaxant Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Type
        • 7.3.3.2.2. By Route of Administration
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. France Muscle Relaxant Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Type
        • 7.3.4.2.2. By Route of Administration
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Muscle Relaxant Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Type
        • 7.3.5.2.2. By Route of Administration
        • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Muscle Relaxant Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Type
    • 8.2.2. By Route of Administration
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Muscle Relaxant Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Type
        • 8.3.1.2.2. By Route of Administration
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India Muscle Relaxant Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Type
        • 8.3.2.2.2. By Route of Administration
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Japan Muscle Relaxant Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Type
        • 8.3.3.2.2. By Route of Administration
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. South Korea Muscle Relaxant Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Type
        • 8.3.4.2.2. By Route of Administration
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia Muscle Relaxant Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Type
        • 8.3.5.2.2. By Route of Administration
        • 8.3.5.2.3. By Distribution Channel

9. South America Muscle Relaxant Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Type
    • 9.2.2. By Route of Administration
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Muscle Relaxant Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Type
        • 9.3.1.2.2. By Route of Administration
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. Argentina Muscle Relaxant Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Type
        • 9.3.2.2.2. By Route of Administration
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. Colombia Muscle Relaxant Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Type
        • 9.3.3.2.2. By Route of Administration
        • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Muscle Relaxant Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Type
    • 10.2.2. By Route of Administration
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Muscle Relaxant Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Type
        • 10.3.1.2.2. By Route of Administration
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Saudi Arabia Muscle Relaxant Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Type
        • 10.3.2.2.2. By Route of Administration
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. UAE Muscle Relaxant Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Type
        • 10.3.3.2.2. By Route of Administration
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Muscle Relaxant Drugs Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. Amneal Pharmaceuticals LLC
    • 14.1.1. Business Overview
    • 14.1.2. Product & Service Offerings
    • 14.1.3. Recent Developments
    • 14.1.4. Financials (If Listed)
    • 14.1.5. Key Personnel
    • 14.1.6. SWOT Analysis
  • 14.2. Ipsen Biopharmaceuticals Inc
  • 14.3. Merz Pharmaceuticals LLC
  • 14.4. Par Pharmaceutical Inc
  • 14.5. Endo Pharmaceuticals Inc
  • 14.6. Vertical Pharmaceuticals Inc
  • 14.7. Mallinckrodt LLC
  • 14.8. Sterix Ltd
  • 14.9. Eisai Co Ltd
  • 14.10.Teva Pharmaceuticals USA Inc.

15. Strategic Recommendations

16. About Us & Disclaimer